**1% Sodium Hyaluronate**

**Product Information**

**CONTENT**

Each prefilled syringe of 1% sodium hyaluronate contains:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Hyaluronate</td>
<td>20 mg</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>17 mg</td>
</tr>
<tr>
<td>Disodium hydrogen phosphate, heptahydrate</td>
<td>0.8 mg</td>
</tr>
<tr>
<td>Sodium dihydrogen phosphate, monohydrate</td>
<td>0.06 mg</td>
</tr>
<tr>
<td>Water for injection</td>
<td>q.s.* to 2.0 mL</td>
</tr>
</tbody>
</table>

*q.s. = up to*

**DESCRIPTION**

1% sodium hyaluronate is a sterile, non-pyrogenic, clear, viscoelastic solution of hyaluronan contained in a single-use prefilled syringe. 1% sodium hyaluronate is a viscous solution of sodium hyaluronate in buffered physiological sodium chloride. Sodium hyaluronate is a high molecular weight fraction (approximately 2.5x10^6 daltons) of a natural complex sugar polymer consisting of the repeating disaccharide units Na-glucuronate-N acetylglucosamine.

**INDICATIONS**

1% sodium hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).

**CONTRAINDICATIONS**

- Do not use 1% sodium hyaluronate to treat patients who have a known hypersensitivity to hyaluronan preparations.
- Do not use to treat patients with knee joint infections or to treat patients with infections or skin disease in the area of the injection site.

**WARNINGS**

- Do not concomitantly use disinfectants containing quaternary ammonium salts or chlorhexidine for skin preparations because hyaluronan can precipitate in their presence.
- Do not inject intravascularly because intravascular injections of 1% sodium hyaluronate may cause systemic adverse events.

**PRECAUTIONS**

- Patients having repeated exposure to 1% sodium hyaluronate have the potential for an immune response; however, this has not been assessed in humans.
- The safety and effectiveness of injection of 1% sodium hyaluronate in conjunction with other intra-articular injectables, or into joints other than the knee have not been established.
- Remove any joint effusion before injecting.
- Transient pain or swelling of the injected joint may occur after intra-articular injection with 1% sodium hyaluronate.
- The effectiveness of repeated injection cycles of 1% sodium hyaluronate has not been established.
- The contents of the syringe must be used immediately after its packaging is opened. Do not re-sterilize the product.
- Strict aseptic administration technique must be followed.
- Do not re-use. Dispose of the syringe and any unused 1% sodium hyaluronate after use.
- Do not use if the syringe blister package is opened or damaged.
- The route for intra-articular injection should be chosen so that damage to adjacent vital structures is avoided.
- An increase in injection pressure may indicate incorrect extra-articular placement of the needle or overfilling of the joint.
- Local anesthetics should not be used if the patient is known to be allergic or sensitive to local anesthetic.
- 1% sodium hyaluronate should be used with caution in patients with pre-existing chondrocalcinosis as injection may lead to an acute attack of the condition.
As with any viscosupplementation treatment, the patient should avoid any strenuous activities or prolonged (i.e. more than an hour) weight bearing activities within 48 hours following intra-articular injection.

**USE IN SPECIFIC POPULATIONS**

**Pregnancy**
The safety and effectiveness of 1% sodium hyaluronate have not been established in pregnant women.

**Nursing Mothers**
It is not known if 1% sodium hyaluronate is excreted in human milk. The safety and effectiveness of 1% sodium hyaluronate have not been established in lactating women.

**Children**
The safety and effectiveness of 1% sodium hyaluronate have not been demonstrated in children (21 years of age or younger).

**ADVERSE REACTIONS**

Adverse event information regarding the use of 1% sodium hyaluronate as a treatment for pain in OA of the knee was available from a 26-week multicenter clinical trial conducted in the United States. This study was a three-arm prospective, randomized, double-blind, multicenter study conducted in 33 centers. Table 1 shows the summary of treatment emergent adverse events occurring in ≥1% of patients participating in this trial who received 1% sodium hyaluronate.

**Table 1**
**Summary of Treatment Emergent Adverse Events (TEAEs)* Occurring in ≥ 1% of Patients (Safety Analysis Population)**

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Placebo N=197 n (%)</th>
<th>Euflexxa® N=199 n (%)</th>
<th>1% Sodium Hyaluronate N=199 n (%)</th>
<th>Total N=595 n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with Any TEAE(s)</td>
<td>76 (38.6)</td>
<td>82 (41.2)</td>
<td>76 (38.2)</td>
<td>234 (39.3)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>2 (1.0)</td>
<td>2 (1.0)</td>
<td>4 (0.7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>1 (0.5)</td>
<td>0</td>
<td>2 (1.0)</td>
<td>3 (0.5)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site joint pain</td>
<td>12 (6.1)</td>
<td>1 (0.5)</td>
<td>5 (2.5)</td>
<td>18 (3.0)</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>1 (0.5)</td>
<td>2 (1.0)</td>
<td>2 (1.0)</td>
<td>5 (0.8)</td>
</tr>
<tr>
<td>Edema peripheral</td>
<td>2 (1.0)</td>
<td>1 (0.5)</td>
<td>2 (1.0)</td>
<td>5 (0.8)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper respiratory tract infections</td>
<td>3 (1.5)</td>
<td>7 (3.5)</td>
<td>7 (3.5)</td>
<td>17 (2.9)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>8 (4.1)</td>
<td>3 (1.5)</td>
<td>5 (2.5)</td>
<td>16 (2.7)</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>0</td>
<td>1 (0.5)</td>
<td>5 (2.5)</td>
<td>6 (1.0)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>2 (1.0)</td>
<td>2 (1.0)</td>
<td>2 (1.0)</td>
<td>6 (1.0)</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>0</td>
<td>0</td>
<td>2 (1.0)</td>
<td>2 (0.3)</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle strain</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
<td>2 (1.0)</td>
<td>4 (0.7)</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>24 (12.2)</td>
<td>26 (13.1)</td>
<td>19 (9.5)</td>
<td>69 (11.6)</td>
</tr>
<tr>
<td>Joint swelling</td>
<td>7 (3.6)</td>
<td>3 (1.5)</td>
<td>5 (2.5)</td>
<td>15 (2.5)</td>
</tr>
<tr>
<td>Joint crepitation</td>
<td>4 (2.0)</td>
<td>3 (1.5)</td>
<td>5 (2.5)</td>
<td>15 (2.5)</td>
</tr>
<tr>
<td>Joint effusion</td>
<td>4 (2.0)</td>
<td>2 (1.0)</td>
<td>4 (2.0)</td>
<td>10 (1.7)</td>
</tr>
<tr>
<td>Back pain</td>
<td>3 (1.5)</td>
<td>3 (1.5)</td>
<td>2 (1.0)</td>
<td>8 (1.3)</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>0</td>
<td>1 (0.5)</td>
<td>3 (1.5)</td>
<td>4 (0.7)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* TEAEs: Treatment Emergent Adverse Events
<table>
<thead>
<tr>
<th></th>
<th>1% Sodium Hyaluronate</th>
<th>Placebo</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>5 (2.5)</td>
<td>3 (1.5)</td>
<td>3 (1.5)</td>
</tr>
<tr>
<td>Sciatica</td>
<td>0</td>
<td>1 (0.5)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>0</td>
<td>2 (1.0)</td>
<td>3 (1.5)</td>
</tr>
</tbody>
</table>

* TEAEs were defined as those adverse events which worsened in severity on or after the date of first administration of study device or with onset date on or after date of first administration of study device.

- N/n = number of subjects
- Euflexxa® is a registered trademark of Ferring BV.

The incidence of target knee-related treatment emergent adverse events was comparable with the placebo group [32 (16.1%) subjects in the 1% sodium hyaluronate group versus 45 (22.8%) subjects in the placebo group]. The most common target-knee related treatment-emergent adverse event, by preferred term, was arthralgia [17 (8.5%) subjects in the 1% sodium hyaluronate group versus 21 (10.7%) subjects in the placebo group].

The incidence of device-related treatment emergent adverse events was low and comparable with the placebo group [7 (3.5%) subjects in the 1% sodium hyaluronate group versus 11 (5.6%) subjects in the placebo group]. The most common device-related TEAE, by preferred term, was injection site joint pain [2 (1.0%) subject in the 1% sodium hyaluronate group versus 5 (2.5%) in the placebo group].

The incidence of injection-related treatment emergent adverse events was low and comparable with the placebo group [10 (5.0%) subjects in the 1% sodium hyaluronate group versus 12 (6.1%) subjects in the placebo group]. The most common injection-related treatment emergent adverse event, by preferred term was Injection site joint pain [3 (1.5%) subjects in the 1% sodium hyaluronate group versus 7 (3.6%) subjects in the placebo group].

The incidence of serious adverse events (SAEs) in the 1% sodium hyaluronate group was low and comparable with the placebo group [5 (2.5%) subjects in the 1% sodium hyaluronate group versus 3 (1.5%) subjects in the placebo group]. None of the SAEs were considered to be target-knee related, device-related or injection-related. There were no unanticipated adverse device effects in the study. There were no deaths in the study.

The incidence of TEAEs (Target-knee TEAEs, Device-related TEAEs and Injection-related TEAEs) in 1% sodium hyaluronate was comparable with Euflexxa®.

**POTENTIAL ADVERSE EFFECTS OF THE DEVICE ON HEALTH**

Potential adverse effects (e.g., complications) associated with the use of this device and, in general, associated with intra-articular injection devices for the treatment of pain in osteoarthritis of the knee, include:

- Aggrivated osteoarthritis
- Injection site reaction
- Arthralgia (knee pain)
- Localized osteoarthritis
- Arthropathy
- Joint (knee) disorder
- Arthrosis
- Joint (knee) swelling
- Baker’s cyst
- Joint (knee) effusion
- Bursitis
- Joint (knee) stiffness
- Immune response
- Pain in limb
- Infection
- Paraesthesia
- Injection site erythema
- Phlebitis
- Injection site edema
- Pruritus
- Injection site pain
- Tendonitis
Incidences of rash, headache, dizziness, chills, hives, nausea, muscle cramps, peripheral edema, and malaise have also been reported in association with intra-articular injections.

A summary of the frequency and rate of adverse events identified in the clinical study for 1% sodium hyaluronate is provided in the “Clinical Studies” section.

**CLINICAL STUDIES**

The safety and effectiveness of 1% sodium hyaluronate was evaluated in a double-blind, prospective, multi-site, randomized, three-arm, parallel group, pivotal trial in adult subjects. The primary objective of the study was to evaluate the effectiveness of three weekly intra-articular doses of 2 mL of 1% sodium hyaluronate as compared to placebo injected into the target knee for the treatment of pain in subjects with osteoarthritis. The safety and effectiveness of 1% sodium hyaluronate was also compared with Euflexxa®.

The primary effectiveness endpoint was the change from Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC®) pain score in the target knee at Week 26. Secondary effectiveness endpoints were the change from Baseline in the WOMAC® pain score over time; pain, stiffness and physical function of the target knee as assessed by WOMAC® over time; and the change from Baseline in the Short Form (36) (SF-36) over time. Overall, 595 (99.3%) subjects were treated and 543 (90.7%) subjects completed the study.

Demographic and baseline characteristics for subjects participating in the study are described in Table 2 and were generally similar across treatment groups.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Demographic and Baseline Characteristics for Study Participants [Intent-to-Treat (ITT)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
<td>Placebo Group (N=199)</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>62.0 ± 10.0</td>
</tr>
<tr>
<td>Sex (n, %)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>89 (44.7)</td>
</tr>
<tr>
<td>Female</td>
<td>110 (55.3)</td>
</tr>
<tr>
<td>Target Knee (n, %)</td>
<td></td>
</tr>
<tr>
<td>Right</td>
<td>95 (47.7)</td>
</tr>
<tr>
<td>Left</td>
<td>104 (52.3)</td>
</tr>
<tr>
<td>Target Knee – Tenderness (n, %)</td>
<td>6 (3.0)</td>
</tr>
<tr>
<td>Target Knee – Swelling (n, %)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Target Knee – Redness/Heat (n, %)</td>
<td>0</td>
</tr>
<tr>
<td>Target Knee – Effusion (n, %)</td>
<td>0</td>
</tr>
<tr>
<td>Target Knee Kellgren-Lawrence Grade 2 (n, %)</td>
<td>104 (52.3)</td>
</tr>
<tr>
<td>Target Knee Kellgren-Lawrence Grade 3 (n, %)</td>
<td>95 (47.7)</td>
</tr>
<tr>
<td>Target Knee Kellgren-Lawrence Grade 4 (n, %)</td>
<td>0</td>
</tr>
<tr>
<td>Duration for Target Knee Pain in last Month (Days; mean ± SD)</td>
<td>27.5 ± 4.7</td>
</tr>
</tbody>
</table>

This investigation was conducted as an adaptive investigation with two blinded interim analyses (after approximately 50% and 75% of the planned sample size), allowing for sample size reassessment as needed. No adjustments were deemed necessary after the interim analyses. The investigation was conducted over 16 months, from initiation to last subject, last visit. The investigation was considered complete (primary endpoint completion) once all subjects had completed the Week 26 follow-up visit. The duration of treatment for each subject was 3 weeks, with 23 weeks subsequent follow-up.

**Study Results**
Safety Results

The analysis of safety was based on the Safety Analysis Population cohort of 595 treated patients. The adverse effects and key safety outcomes for this study are presented below in Tables 6 to 10.

Overall, the incidence of Treatment-Emergent Adverse Events (TEAEs) in the 1% sodium hyaluronate treatment group was similar to that of the saline placebo treatment group. In total, 234 (39.3%) subjects experienced 411 TEAEs: 147 TEAEs in the placebo group; 135 TEAEs in the Euflexxa® group; 129 TEAEs in the 1% sodium hyaluronate group. In total, 9 (1.5%) subjects (3 [1.5%] subjects placebo group; 1 [0.5%] subject Euflexxa® group; 5 [2.5%] subjects 1% sodium hyaluronate group) had a treatment-emergent serious adverse event (SAE).

There were 8 (1.3%) subjects with severe TEAEs in total. In all, there were 114 (19.2%) subjects with target knee-related TEAEs (45 [22.8%] subjects placebo group; 37 [18.6%] subjects Euflexxa® group; 32 [16.1%] subjects 1% sodium hyaluronate group) and 31 (5.2%) subjects with any injection-related TEAEs (12 [6.1%] subjects placebo group; 9 [4.5%] subject Euflexxa® group; 10 [5.0%] subjects 1% sodium hyaluronate group). There were no deaths or unexpected adverse device event (UADEs) in the study. Overall TEAEs are summarized below in Table 3.

### Table 3: Overall Summary of TEAEs – Safety Analysis Population

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=197)</th>
<th>Euflexxa® (N=199)</th>
<th>1% Sodium Hyaluronate (N=199)</th>
<th>Total (N=595)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TEAE(s)</td>
<td>147 (n=197)</td>
<td>135 (n=199)</td>
<td>129 (n=199)</td>
<td>411 (n=595)</td>
</tr>
<tr>
<td>Subjects with Any TEAE(s)</td>
<td>76 (38.6)</td>
<td>82 (41.2)</td>
<td>76 (38.2)</td>
<td>234 (39.3)</td>
</tr>
<tr>
<td>Subjects with Any Serious Adverse Event</td>
<td>3 (1.5)</td>
<td>1 (0.5)</td>
<td>5 (2.5)</td>
<td>9 (1.5)</td>
</tr>
<tr>
<td>Subjects with Any Severe TEAE(s)</td>
<td>3 (1.5)</td>
<td>2 (1.0)</td>
<td>3 (1.5)</td>
<td>8 (1.3)</td>
</tr>
<tr>
<td>Subjects with Any Target Knee-Related TEAE(s)</td>
<td>45 (22.8)</td>
<td>37 (18.6)</td>
<td>32 (16.1)</td>
<td>114 (19.2)</td>
</tr>
<tr>
<td>Subjects with Any Device-Related TEAE(s)</td>
<td>11 (5.6)</td>
<td>10 (5.0)</td>
<td>7 (3.5)</td>
<td>28 (4.7)</td>
</tr>
<tr>
<td>Subjects with Any Injection-Related TEAE(s)</td>
<td>12 (6.1)</td>
<td>9 (4.5)</td>
<td>10 (5.0)</td>
<td>31 (5.2)</td>
</tr>
<tr>
<td>Subjects with Any Unanticipated Adverse Device Effect</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Subjects with TEAE(s) Leading to Study Discontinuation</td>
<td>1 (0.5)</td>
<td>0</td>
<td>4 (2.0)</td>
<td>5 (0.8)</td>
</tr>
<tr>
<td>Subjects with TEAE(s) Leading to Death</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Note: TEAEs were those AEs which worsened in severity on or after date of first administration of study device or with onset date on or after date of first administration of study device.

Except for the number of AEs, subjects were counted only once per treatment in each row.

MedDRA V18.1 coding dictionary was used.

Abbreviation: AE(s)=adverse event(s); MedDRA=Medical Dictionary for Regulatory Activities; N/n=number of subjects; SAE=serious adverse event; TEAE(s)=treatment-emergent adverse events.

1. For each subject, multiple AEs sharing the same MedDRA preferred term were counted only once.

Overall, the most frequently experienced TEAEs (all causalities) by System Organ Class for the Safety Analysis Set were:

- Musculoskeletal and connective tissue disorders: the three most common TEAEs (all causalities) by Preferred Term (PT) were:
  - Arthralgia: 69 (11.6%) subjects (24 [12.2%] subjects placebo group; 26 [13.1%] subject Euflexxa® group; 19 [9.5%] subjects 1% sodium hyaluronate group)
  - Joint swelling: 15 (2.5%) subjects (7 [3.6%] subjects placebo group; 3 [1.5%] subject Euflexxa® group; 5 [2.5%] subjects 1% sodium hyaluronate group)
  - Joint crepitation: 12 (2.0%) subjects (4 [2.0%] subjects placebo group; 3 [1.5%] subject Euflexxa® group; 5 [2.5%] subjects 1% sodium hyaluronate group)
Infections and infestations: the three most common TEAEs (all causalities) by PT were:

- Upper respiratory tract infection: 17 (2.9%) subjects (3 [1.5%] subjects placebo group; 7 [3.5%] subject Euflexxa® group; 7 [3.5%] subjects 1% sodium hyaluronate group)
- Nasopharyngitis: 16 (2.7%) subjects (8 [4.1%] subjects placebo group; 3 [1.5%] subject Euflexxa® group; 5 [2.5%] subjects 1% sodium hyaluronate group)
- Bronchitis: 6 (1.0%): (0 subjects placebo group; 1 [0.5%] subject Euflexxa® group; 5 [2.5%] subjects 1% sodium hyaluronate group) and Urinary tract infection: 6 (1.0%): 2 (1.0%) in each treatment group

General disorders and administration site conditions: the three most common TEAEs (all causalities) by PT were:

- Injection site joint pain: 18 (3.0%) (12 [6.1%] subjects placebo group; 1 [0.5%] subject Euflexxa® group; 5 [2.5%] subjects 1% sodium hyaluronate group)
- Injection site joint effusion: 8 (1.3%) (3 [1.5%] subjects placebo group; 4 [2.0%] subject Euflexxa® group; 1 [0.5%] subjects 1% sodium hyaluronate group)
- Injection site joint swelling: 6 (1.0%) (3 [1.5%] subjects placebo group; 2 [1.0%] subject Euflexxa® group; 1 [0.5%] subjects 1% sodium hyaluronate group)

Overall, in the 1% sodium hyaluronate group the incidence of target knee-related TEAEs was comparable with that of the placebo group (32 [16.1%] subjects in the 1% sodium hyaluronate group versus 45 [22.8%] subjects in the placebo group).

Target knee-related TEAEs were most commonly associated with the musculoskeletal and connective tissue disorders SOC (26 [13.2%] subjects in the placebo group, 27 [13.6%] subjects in the Euflexxa® group, 23 [11.6%] subjects in the 1% sodium hyaluronate group) and the general disorders and administration site conditions SOC (18 [9.1%] subjects in the placebo group, 10 [5.0%] subjects in the Euflexxa® group, 9 [4.5%] subjects in the 1% sodium hyaluronate group).

The three most common target knee-related TEAEs, by PT were arthralgia (21 [10.7%] subjects in the placebo group, 24 [12.1%] subjects in the Euflexxa® group, 17 [8.5%] subjects in the 1% sodium hyaluronate group), injection site joint pain (12 [6.1%] subjects in the placebo group, 1 [0.5%] subjects in the Euflexxa® group, 5 [2.5%] subjects in the 1% sodium hyaluronate group) and joint swelling (6 [3.0%] subjects in the placebo group, 2 [1.0%] subjects in the Euflexxa® group, 5 [2.5%] subjects in the 1% sodium hyaluronate group).

Target knee-related TEAEs are summarized by SOC and PT in Table 4 below.

### Table 4:
**Summary of Target Knee-Related TEAEs by SOC and PT—Safety Analysis**

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Placebo N=197</th>
<th>Euflexxa® N=199</th>
<th>1% Sodium Hyaluronate N=199</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred Term</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Subjects with any Target Knee-Related TEAEs</td>
<td>45 (22.8)</td>
<td>37 (18.6)</td>
<td>32 (16.1)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site bruising</td>
<td>1 (0.5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Injection site erythema</td>
<td>0</td>
<td>2 (1.0)</td>
<td>0</td>
</tr>
<tr>
<td>Injection site haemorrhage</td>
<td>1 (0.5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Injection site joint effusion</td>
<td>3 (1.5)</td>
<td>4 (2.0)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Injection site joint pain</td>
<td>12 (6.1)</td>
<td>1 (0.5)</td>
<td>5 (2.5)</td>
</tr>
<tr>
<td>Injection site joint swelling</td>
<td>3 (1.5)</td>
<td>2 (1.0)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Injection site joint warmth</td>
<td>0</td>
<td>2 (1.0)</td>
<td>0</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>1 (0.5)</td>
<td>2 (1.0)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Injection site reaction</td>
<td>1 (0.5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Injection site swelling</td>
<td>1 (0.5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mass</td>
<td>0</td>
<td>1 (0.5)</td>
<td>0</td>
</tr>
<tr>
<td>Swelling</td>
<td>0</td>
<td>0</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Tenderness</td>
<td>0</td>
<td>0</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site infection</td>
<td>0</td>
<td>1 (0.5)</td>
<td>0</td>
</tr>
</tbody>
</table>
Injury, poisoning and procedural complications 4 (2.0) 2 (1.0) 1 (0.5)
Contusion 1 (0.5) 0 0
Laceration 0 0 1 (0.5)
Meniscus injury 0 1 (0.5) 0
Muscle rupture 1 (0.5) 0 0
Procedural pain 0 1 (0.5) 0
Skin abrasion 1 (0.5) 1 (0.5) 0
Soft tissue injury 1 (0.5) 0 0
Musculoskeletal and connective tissue disorders 26 (13.2) 27 (13.6) 23 (11.6)
Arthralgia 21 (10.7) 24 (12.1) 17 (8.5)
Exostosis 0 2 (1.0) 0
Haemarthrosis 1 (0.5) 0 0
Joint crepitation 4 (2.0) 3 (1.5) 4 (2.0)
Joint effusion 4 (2.0) 2 (1.0) 4 (2.0)
Joint range of motion decreased 1 (0.5) 1 (0.5) 0
Joint stiffness 1 (0.5) 0 1 (0.5)
Joint swelling 6 (3.0) 2 (1.0) 5 (2.5)
Joint warmth 1 (0.5) 0 0
Osteoarthritis 0 1 (0.5) 1 (0.5)
Tendonitis 1 (0.5) 0 0
Nervous system disorders 2 (1.0) 0 0
Paraesthesia 1 (0.5) 0 0
Presyncope 1 (0.5) 0 0
Psychiatric disorders 1 (0.5) 0 0
Depression 1 (0.5) 0 0
Skin and subcutaneous tissue disorders 2 (1.0) 0 0
Erythema 2 (1.0) 0 0

Overall, in the 1% sodium hyaluronate group the incidence of device-related TEAEs was low and comparable with the placebo group (7 [3.5%] subjects in the 1% sodium hyaluronate group versus 11 [5.6%] subjects in the placebo group).

The three most common device-related TEAEs, by PT were injection site joint pain (5 [2.5%] subjects in the placebo group, 1 [0.5%] subjects in the Euflexxa® group, 2 [1.0%] subjects in the 1% sodium hyaluronate group), arthralgia (2 [1.0%] subjects in the placebo group, 4 [2.0%] subjects in the Euflexxa® group, 2 [1.0%] subjects in the 1% sodium hyaluronate group) and injection site joint effusion (2 [1.0%] subjects in the placebo group, 1 [0.5%] subjects in the Euflexxa® group, 1 [0.5%] subjects in the 1% sodium hyaluronate group).

Device-related TEAEs by SOC and PT are summarized below in Table 5.

**Table 5:** Summary of Device-Related TEAEs by SOC and PT – Safety Analysis Population

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Placebo N=197</th>
<th>Euflexxa® N=197</th>
<th>1% Sodium Hyaluronate N=199</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred Term</td>
<td>n(%)</td>
<td>n(%)</td>
<td>n(%)</td>
</tr>
<tr>
<td>Subjects with any Device-related TEAEs</td>
<td>11 (5.6)</td>
<td>10(5.0)</td>
<td>7 (3.5)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>8 (4.1)</td>
<td>5 (2.5)</td>
<td>4 (2.0)</td>
</tr>
<tr>
<td>Injection site erythema</td>
<td>0</td>
<td>1(0.5)</td>
<td>0</td>
</tr>
<tr>
<td>Injection site joint effusion</td>
<td>2 (1.0)</td>
<td>1(0.5)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Injection site joint pain</td>
<td>5 (2.5)</td>
<td>1(0.5)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Injection site joint swelling</td>
<td>0</td>
<td>2(1.0)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Injection site joint warmth</td>
<td>0</td>
<td>1(0.5)</td>
<td>0</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>0</td>
<td>1(0.5)</td>
<td>1 (0.5)</td>
</tr>
</tbody>
</table>
### Table 6
Change in WOMAC® Pain Score from Baseline to Week 26 in Intent-to-Treat (ITT) Population

<table>
<thead>
<tr>
<th></th>
<th>1% Sodium Hyaluronate</th>
<th>Placebo</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Change from baseline</td>
<td>N</td>
<td>Change from baseline</td>
</tr>
<tr>
<td></td>
<td>(mean ± SD)</td>
<td></td>
<td>(mean ± SD)</td>
</tr>
<tr>
<td>Intent-to-Treat Population</td>
<td>-168 mm ± 129 mm</td>
<td>199</td>
<td>-132 mm ± 128 mm</td>
</tr>
</tbody>
</table>

WOMAC® is a registered trademark of Nicholas Bellamy.

---

**Primary Effectiveness Results**

At the Week 26 visit the LSmean (standard deviation [SD]) change from Baseline in WOMAC® pain scores were -132 mm ± 128 mm in the placebo group versus -168 mm ± 129 mm in the 1% sodium hyaluronate group (Table 6, Figure 1). At the Week 26 visit the difference (placebo versus 1% sodium hyaluronate) in LSmean change from Baseline in WOMAC® pain score was significantly greater for the 1% sodium hyaluronate group versus the placebo group [36 mm (95% CI: 10.25; 62.11)] demonstrating the superiority of 1% sodium hyaluronate to placebo.
Secondary Effectiveness Results

The following secondary effectiveness endpoints were evaluated using 1% sodium hyaluronate, placebo and Euflexxa®:

- The change from Baseline in the WOMAC® pain score over time
- Pain, stiffness and physical function of the target knee as assessed by WOMAC® over time
- The change from Baseline in the Short Form (36) (SF-36) over time.

Over time, the mean (SD) percentage change of WOMAC® pain score from Baseline was greater for 1% sodium hyaluronate compared with placebo. From Week 6 through Week 26 visits, the differences (placebo versus 1% sodium hyaluronate) in LSmean change of WOMAC® pain score from Baseline were significantly larger for the 1% sodium hyaluronate group versus the placebo group, thus demonstrating superiority of 1% sodium hyaluronate to placebo. At Week 6, the difference (placebo versus 1% sodium hyaluronate) in LSmean of WOMAC® pain score from Baseline was 26 mm (95% CI: 2.26; 50.39) and increased through Week 26 [36 mm (95% CI: 10.25; 62.11)].

Over time, the mean (SD) percentage change from Baseline in WOMAC® stiffness score was greater for 1% sodium hyaluronate compared with placebo. At Week 26, for the ITT population, the mean (SD) percentage change from Baseline was higher for 1% sodium hyaluronate [-47.37% (45.275)] compared with placebo [-35.77% (63.103)]. From Week 2 through Week 26 visits, the magnitude of LSmean change of WOMAC® stiffness score from Baseline was greater for the 1% sodium hyaluronate group versus the placebo group and statistically significantly greater at Weeks 6, 12, and 26 (ITT population).

Over time, the mean (SD) percentage change from Baseline in WOMAC® stiffness score was similar for 1% sodium hyaluronate compared with Euflexxa®. At Week 26, for the ITT population, the mean (SD) percentage change from Baseline was similar for 1% sodium hyaluronate [-47.37% (45.275)] compared with Euflexxa® [-47.25% (63.020)].

At the Week 26 visit, the mean (SD) WOMAC® Physical Function Score was 659 mm (465.305) in the placebo group compared with 567 mm (467.059) in the 1% sodium hyaluronate group, where higher WOMAC® score reflected worse physical function. At Week 26, for the ITT population, the mean (SD) percentage change from Baseline was higher for 1% sodium hyaluronate [-48.99% (40.163)] compared with placebo [-37.37% (49.555)].

Over time, the mean (SD) percentage change from Baseline in WOMAC® Physical Function Score was similar for 1% sodium hyaluronate compared with Euflexxa®. At Week 26, for the ITT population, the mean (SD) percentage change from Baseline was similar for 1% sodium hyaluronate [-48.99% (40.163)] compared with Euflexxa® [-53.67% (35.781)].
LSmean increases from Baseline in SF-36 Physical Functioning, Bodily Pain, General Health, Vitality, and Role Emotional scores were observed for the 1% sodium hyaluronate group versus the placebo group. At Week 26, LSmean increases from Baseline in SF-36 were noted for SF-36 Physical Component Summary (PCS), Mental Component Summary (MCS). The observed increases did not reach statistical significance [95% CI for the difference (placebo versus 1% sodium hyaluronate) included 0].

At Baseline, the mean (SD) WOMAC® Physical Function Score of the target knee was 1096 mm (294.338) in the placebo group compared with 1136 mm (330.307) in the 1% sodium hyaluronate group. At the Week 26 visit, the mean (SD) WOMAC® Physical Function Score was 659 mm (465.305) in the placebo group compared with 567 mm (467.059) in the 1% sodium hyaluronate group, where higher WOMAC® score reflect worse physical function.

From Week 2 through Week 26 visits, the magnitude of LSmean change of WOMAC® Physical Function Score from Baseline was greater for the 1% sodium hyaluronate group versus the placebo group and significantly greater at Weeks 6, 12, 18 and 26 (ITT population). Over time, the mean (SD) percentage change from Baseline was greater for 1% sodium hyaluronate compared with placebo. At Week 26, for the ITT population, the mean (SD) percentage change from Baseline was higher for 1% sodium hyaluronate [-48.99% (40.163)] compared with placebo [37.37% (49.555)].

Over time, the mean (SD) percentage change from Baseline of WOMAC® Physical Function Score was similar for 1% sodium hyaluronate compared with Euflexxa®. At Week 26 (for the ITT population) the mean (SD) percentage change from Baseline was similar for 1% sodium hyaluronate [-48.99% (40.163)] compared with Euflexxa® [-53.67% (35.781)].

Rescue medication use was comparable between treatment groups. From Day 1 through Week 26, the mean (SD) number of acetaminophen caplets administered was 120.6 (141.92), 108.5 (149.59) and 102.1 (124.41) for the placebo group, Euflexxa® group and 1% sodium hyaluronate group, respectively.

HOW SUPPLIED

1% sodium hyaluronate is supplied in a 3 mL disposable prefilled glass syringe containing 2 mL of 1% sodium hyaluronate. Only the contents of the syringe are sterile. Each syringe is individually sealed in a blister, and three syringe blisters are included in each carton.

Product Code: 57844-181-13

This product is not made with natural rubber latex.

STORAGE INSTRUCTIONS

Do not use 1% sodium hyaluronate if the package is open or damaged. Store in original package at 2°-25°C (36°-77°F). Protect from light. Do not freeze.

Caution: Federal law restricts this device to sale by or on the order of a physician.

DIRECTIONS FOR USE

- 1% sodium hyaluronate is a single administration preparation and should be injected into the knee joint in a series of intra-articular injections one week apart for a total of three injections.
- Carefully disinfect the injection site according to standard medical practice. Avoid using disinfectants containing quaternary ammonium salts such as benzalkonium chloride (see WARNINGS).
- Anesthetization of the injection site is not required; however, a topical or intra-dermal anesthetic (e.g., ethyl chloride or lidocaine) may be used at the discretion of the treating healthcare professional.
- Before initiating the preparation steps below, check if the product is damaged or broken. Do not use if the blister package is opened or damaged.
- After removal of the protective cap on the tip of the syringe (Illustration No. 1), securely attach a small gauge needle (21- or 23-gauge) to the tip. If the protective cap is damaged or there is evidence it has been opened, do not use the product.

Illustration No. 1
Using a lateral upper patellar or lateral mid patellar approach, place needle into the joint (See Illustration 2). Ultrasound may be used to facilitate accurate needle placement of the injection. Inject 1% sodium hyaluronate into the knee joint using strict aseptic administration technique.

**Illustration No. 2**

- Perform gentle aspiration to ascertain that the needle has been properly placed into the joint space.
- Remove any joint fluid.
- Over the course of 2-3 minutes, inject the full 2 mL of the syringe intra-articularly into one knee only.
- Remove syringe and needle from knee joint.
- For single use only. Do not resterilize. After administration, dispose of needle and syringe in appropriate receptacle.
- Repeat the procedure as described above at weekly intervals for three weeks, for a total of three injections.

**Toll-free number for providers and patients to call with questions:** 1-888-838-2872.

**MANUFACTURER INFORMATION**

Manufactured by:
**Hanmi Pharm. Co., Ltd.**
Gyeonggi-do, 18536, Korea

Manufactured for:
**Teva Pharmaceuticals USA, Inc.**
North Wales, PA 19454
Patient Information
1% Sodium Hyaluronate

Be sure to read the following important information carefully. This information does not take the place of your doctor’s advice. If you do not understand this information or want to know more, ask your doctor.

WHAT IS THE 1% SODIUM HYALURONATE?

1% sodium hyaluronate is a gel-like, elastic, sterile product containing highly purified hyaluronan (pronounced hye-a-loo-ROE-nan). Hyaluronan is a natural substance found in the body. It is present in particularly high amounts in joint tissues and in the fluid that fills the joints. The body’s own hyaluronan acts like a lubricant and a shock absorber in the joint. It is needed for the joint to function properly.

WHAT IS 1% SODIUM HYALURONATE USED FOR?

1% sodium hyaluronate is used to help relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

Osteoarthritis is a condition that involves the wearing down of cartilage (the protective covering on the ends of your bones). In osteoarthritis, there may not be enough, or a decrease in the quality, of the gel-like substance in the joint and surrounding tissues for the joint to work properly.

HOW IS 1% SODIUM HYALURONATE GIVEN?

1% sodium hyaluronate comes in pre-filled syringes containing 2 ml (about half a teaspoon) of product. 1% sodium hyaluronate is given by injection directly into the knee joint by a doctor or other qualified healthcare professional in his/her office. 1% sodium hyaluronate is injected into your knee once a week for three weeks, for a total of three injections.

ARE THERE ANY REASONS WHY I SHOULD NOT TAKE 1% SODIUM HYALURONATE?

- Your doctor will determine if you are an appropriate candidate for 1% sodium hyaluronate.

- Do not take 1% sodium hyaluronate if you have had previous allergic reactions to 1% sodium hyaluronate or hyaluronan products.

- 1% sodium hyaluronate should not be injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
WHAT SHOULD MY DOCTOR WARN ME ABOUT?

• After you receive an injection of 1% sodium hyaluronate, you may experience temporary pain or swelling of the injected joint.

• 1% sodium hyaluronate has not been tested in pregnant women or women who are nursing. Tell your doctor if you think you are pregnant or nursing a child before agreeing to be injected with 1% sodium hyaluronate.

• 1% sodium hyaluronate has not been tested in children less than 21 years of age.

WHAT ARE SOME OF THE POSSIBLE SIDE EFFECTS OF 1% SODIUM HYALURONATE?

The following are the most common adverse events that occurred during the clinical trial of 1% sodium hyaluronate:

• Pain in the knee or at the injection site
• Swelling and discomfort of the joint

WHAT ARE THE BENEFITS OF 1% SODIUM HYALURONATE?

Based on the results from a clinical study, subjects with knee pain due to osteoarthritis experienced relief of this pain as well as improvement in knee function lasting up to 6 months after receiving 1% sodium hyaluronate.

WHAT SHOULD I DO AFTER RECEIVING A 1% SODIUM HYALURONATE INJECTION?

• After receiving your injection, limit physical activity. Someone may need to drive you home from the doctor’s office.

• Avoid strenuous physical activity for 48 hours following the injection to help keep your knee from swelling. Some examples of activities to avoid include:
  o Running-Tennis-Hiking
  o Jumping-Swimming-Heavy lifting (weight lifting)
  o Jogging-Bicycling-Aerobic exercise

• Do not stand on your feet for more than one hour at a time during the first 48 hours following your injection.

• You should ask your doctor when you should begin major physical activities again.

WHEN SHOULD I CALL MY DOCTOR (TROUBLESHOOTING)?

If you experience any of the adverse effects or symptoms described earlier or if you have any other problems, you should call your doctor immediately.
ARE THERE OTHER NON-SURGICAL TREATMENTS AVAILABLE FOR OSTEOARTHRITIS?

Yes, there are other non-surgical treatments available. Some of them include, but are not limited to:

- **Non-drug treatments**
  - Avoiding activities that cause pain in your knee
  - Exercise
  - Physical therapy
  - Weight loss (if overweight)
  - Removal of excess fluid from the knee

- **Drug Therapy**
  - Pain medications such as acetaminophen or stronger prescription medications
  - Drugs that reduce inflammation, such as aspirin and other nonsteroidal anti-inflammatory agents (NSAIDs) such as ibuprofen and naproxen
  - Corticosteroids that are injected directly into the joint

Talk to your healthcare professional about non-surgical treatment options that may be appropriate for you.

Manufactured By:
**Hanmi Pharm. Co., Ltd.**
Gyeonggi-do, 18536, Korea

Manufactured For:
**Teva Pharmaceuticals USA, Inc.**
North Wales, PA 19454

Iss. 3/2019